Zogenix (ZGNX) Stock Price, News & Analysis

Company Overview

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Key Stats

• Today's Range: $26.68 to $26.68
• 50-Day Range: $26.10 to $26.68
• 52-Week Range: $11.03 to $26.90
• Volume: 94 shs
• Average Volume: 3.76 million shs
• Market Capitalization: $1.50 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZGNX Stock Analysis - Frequently Asked Questions

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) released its quarterly earnings data on Thursday, November, 4th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by $0.08. The firm's revenue for the quarter was up 690.6% compared to the same quarter last year.
Read the conference call transcript.

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zogenix investors own include Bristol-Myers Squibb (BMY), QUALCOMM (QCOM), Gilead Sciences (GILD), GW Pharmaceuticals (GWPH), Intel (INTC), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 6/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ZGNX
• CIK: 1375151
• Web: www.zogenix.com
• Phone: (510) 550-8300
• Fax: 858-259-1166
• Employees: 218
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$209.38 million
• Net Margins: -278.38%
• Pretax Margin: -278.26%
• Return on Equity: -91.20%
• Return on Assets: -43.60%

Debt

• Debt-to-Equity Ratio: 0.88
• Current Ratio: 3.63
• Quick Ratio: 4.74

Sales & Book Value

• Annual Sales: $81.69 million
• Price / Sales: 18.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.64 per share
• Price / Book: 4.02

Miscellaneous

• Outstanding Shares: 56,227,000
• Free Float: 53,922,000
• Market Cap: $1.50 billion
• Optionable: Optionable
• Beta: 0.89